Given their complementary mechanisms, the combination of denosumab and PD-1/PD-L1 ICIs shows promising synergistic effects in the bone metastatic setting, with improved objective response rate (ORR), prolonged progression-free survival (PFS), and manageable safety profiles in lung cancer patients (13, 14). This evidence concerns the gene CD274 and lung carcinoma.